Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists
30 4월 2020 - 1:00AM
Business Wire
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics
for cancer, today announced the Accreditation Committee of the
College of American Pathologists (CAP) has awarded re-accreditation
to the Personalis Clinical Laboratory, Menlo Park, California based
on results of a recent on-site inspection as part of the CAP’s
Accreditation Programs.
The Personalis Clinical Laboratory was advised of this national
recognition and congratulated for the excellence of the services
being provided. The Personalis Clinical Laboratory is one of more
than 8,000 CAP-accredited facilities worldwide.
“As Personalis has grown to serve more customers, the quality of
our Clinical Laboratory operations has remained critical to our
mission. Our re-accreditation from CAP is the result of daily
efforts by multiple teams, and a testament to the hard work of our
Clinical Laboratory team and the entire organization,” said Massimo
Morra, Executive Medical & Clinical Laboratory Director and
Head of Quality & Regulatory at Personalis, Inc.
“Personalis has been CAP accredited since 2014, demonstrating
our continued excellence in services provided. By maintaining an
exemplary track record of full compliance with CAP Standards our
partners can be assured that we will continue to provide
outstanding quality and service,” said John West, CEO, Personalis,
Inc.
The U.S. federal government recognizes the CAP Laboratory
Accreditation Program, begun in the early 1960s, as being equal to
or more stringent than the government’s own inspection program for
certification under the Clinical Laboratory Improvements Act of
1988, as amended (CLIA’88).
During the CAP accreditation process, designed to ensure the
highest standard of care for all laboratory patients, inspectors
examine the laboratory’s records and quality control of procedures
for the preceding two years. CAP inspectors also examine the
laboratory’s staff qualifications, equipment, facilities, safety
program and record, and overall management.
About the College of American Pathologists
As the world's largest organization of board-certified
pathologists and leading provider of laboratory accreditation and
proficiency testing programs, the College of American Pathologists
(CAP) serves patients, pathologists, and the public by fostering
and advocating excellence in the practice of pathology and
laboratory medicine worldwide. For more information, read the CAP
annual report at cap.org
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis ImmunoID NeXT PlatformTM
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. For
example, forward-looking statements include statements regarding
the future availability and quality of services provided by the
Personalis Clinical Laboratory and other future events. These
forward-looking statements are subject to risks and uncertainties,
including those related to the evolution of cancer therapies and
market adoption of our services, our expectations regarding future
performance, and the COVID-19 pandemic, as well as other risks and
uncertainties discussed in Personalis’ filings with the Securities
and Exchange Commission (SEC), including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of the Company’s most recently
filed periodic reports on Forms 10-K and 10-Q and subsequent
filings and in the documents incorporated by reference therein, all
of which may significantly impact our business and operations, the
business and operations of our customers, our ability to access
capital and the value of our common stock. Except as otherwise
required by law, Personalis disclaims any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date hereof, whether as a result of new information,
future events or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200429005591/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com 415-202-5678
Media Contact: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024